1. Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202
- Author
-
Shunji Endo, Kazuyoshi Yamamoto, Kouji Kobayashi, Ryohei Kawabata, Hirokazu Taniguchi, Atsushi Takeno, Yukinori Kurokawa, Toru Masuzawa, Yutaka Kimura, Taroh Satoh, Daisuke Sakai, Jin Matsuyama, Makio Gamoh, Junji Kawada, and Toshio Shimokawa
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Receptor, ErbB-2 ,Nausea ,Anemia ,Kaplan-Meier Estimate ,Neutropenia ,Gastroenterology ,Disease-Free Survival ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Stomach Neoplasms ,Trastuzumab ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Neoplasm Metastasis ,Adverse effect ,Aged ,Tegafur ,Cisplatin ,business.industry ,Cancer ,General Medicine ,Middle Aged ,medicine.disease ,Drug Combinations ,Oxonic Acid ,Regimen ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
Background/aim Trastuzumab with S-1 plus cisplatin was proved to be effective for human epidermal growth factor receptor type 2 (HER2)-positive advanced gastric cancer with measurable lesions. However, the efficacy and safety of this regimen in the absence of measurable lesions are unknown. Patients and methods Patients with HER2-positive gastric cancer without measurable lesions received cisplatin plus trastuzumab intravenously on day 1 and oral S-1 on days 1-14 of a 21-day cycle. The primary end-point was overall survival, and 40 patients were planned to be enrolled. Results Fifteen patients were enrolled. The median overall survival was 14.4 months. The 1- and 3-year overall survival rates were 66.7 % and 26.7 %, respectively. Major grade 3-4 adverse events included neutropenia (47%), anemia (40%), diarrhea (20%), nausea (20%), and anorexia (20%). Conclusion Trastuzumab with S-1 plus cisplatin might be effective and tolerable for HER2-positive advanced gastric cancer without measurable lesions.
- Published
- 2019